Boston Bio Systems Limited Rebrands as Boston Commerce Limited

BOSTON BIO SYSTEMS LTD. , a company listed on the Bombay Stock Exchange (BSE: 531458), has officially changed its name to Boston Commerce Limited. This corporate rebranding, approved by the Ministry of Corporate Affairs on November 27, 2025, marks a significant milestone in the company's history.

Key Points of the Name Change

Approval Date: November 27, 2025
Former Name: Boston Bio Systems Limited
New Name: Boston Commerce Limited
Shareholder Approval: Obtained through a Special Resolution at the Annual General Meeting on September 30, 2025

Financial Snapshot

While the name change is a significant corporate action, it's also important to consider the company's financial position. Based on the most recent balance sheet data as of March 2025, here's a snapshot of key financial metrics:

Financial Metric	March 2025 (₹ in crore)	Year-on-Year Change
Total Assets	14.90	40.57%
Current Assets	9.10	89.58%
Total Equity	5.90	-9.23%
Current Liabilities	4.40	10.00%
Non-Current Liabilities	4.60	4500.00%

The company has seen significant changes in its financial structure over the past year:

Asset Growth: Total assets increased by 40.57% year-on-year, primarily driven by a substantial 89.58% increase in current assets.
Liability Increase: Non-current liabilities saw a dramatic rise of 4500%, from ₹0.1 crore to ₹4.6 crore.
Equity Position: Total equity decreased by 9.23%, indicating some pressure on the company's net worth.

Implications of the Name Change

The transition from 'Boston Bio Systems' to 'Boston Commerce' suggests a potential shift in the company's business focus or strategy. While the name change itself doesn't directly impact the company's financials, it may signal upcoming changes in business operations or market positioning.

Investors and stakeholders should monitor future announcements from the company for any indications of strategic shifts that may accompany this rebranding effort. As always, it's crucial to consider both corporate actions and financial performance when evaluating a company's prospects.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.15%	-1.04%	-9.43%	-7.27%	-68.28%	-68.28%

BOSTON BIO SYSTEMS LTD. (BSE: BOSTONBIO) has announced its financial results for the second quarter and half-year ended September 30, 2025, alongside key appointments in its auditing team.

Financial Performance

The company reported an improvement in its financial performance for Q2 FY2025-26. Here's a breakdown of the key figures:

Particulars	Q2 FY2025-26	Q2 FY2024-25	H1 FY2025-26	H1 FY2024-25
Revenue	₹24.47 crore	Not available	₹42.52 crore	Not available
Profit After Tax	₹3.94 crore	(₹0.50 crore)	₹7.95 crore	(₹0.50 crore)
EPS (Basic & Diluted)	₹0.06	(₹0.01)	₹0.11	(₹0.01)

The company has shown a turnaround in its profitability compared to the same period last year. The revenue for Q2 FY2025-26 stood at ₹24.47 crore, while the half-yearly revenue reached ₹42.52 crore.

Appointment of Auditors

Boston Bio Systems has made two key appointments:

Secretarial Auditor: Mr. Shashank Kumar, Proprietor of M/s Shashank Kumar & Associates (FRN: S2018UP715500), has been appointed as the Secretarial Auditor for the Financial Year 2025-26.
Internal Auditor: Mr. Nishant Sharma, Proprietor of M/s Vyom Advisors, has been appointed as the Internal Auditor for the Financial Year 2025-26.

Management Commentary

No specific management comments were provided in the available data.

Looking Ahead

As Boston Bio Systems continues to navigate the business landscape, investors and stakeholders may observe how these financial improvements and new appointments contribute to the company's operations and corporate governance practices.